LAVENDER_MEDICAL_LIMITED - Accounts


Company registration number 06828106 (England and Wales)
LAVENDER MEDICAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022
PAGES FOR FILING WITH REGISTRAR
LAVENDER MEDICAL LIMITED
COMPANY INFORMATION
Director
Mr R S Saab
Secretary
Mr S S Saab
Company number
06828106
Registered office
11 Amor Way
Letchworth Garden City
Hertfordshire
United \Kingdom
SG6 1UG
Accountants
Bishops
Phoenix Park
Blakewater Road
Blackburn
Lancashire
BB1 5BG
LAVENDER MEDICAL LIMITED
CONTENTS
Page
Accountants' report
1
Statement of financial position
2 - 3
Notes to the financial statements
4 - 10
LAVENDER MEDICAL LIMITED
ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF LAVENDER MEDICAL LIMITED FOR THE YEAR ENDED 31 DECEMBER 2022
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Lavender Medical Limited for the year ended 31 December 2022 which comprise, the statement of financial position and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the board of directors of Lavender Medical Limited, as a body, in accordance with the terms of our engagement letter dated 1 January 2023. Our work has been undertaken solely to prepare for your approval the financial statements of Lavender Medical Limited and state those matters that we have agreed to state to the board of directors of Lavender Medical Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Lavender Medical Limited and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Lavender Medical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Lavender Medical Limited. You consider that Lavender Medical Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Lavender Medical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Bishops
15 August 2023
Chartered Accountants
Phoenix Park
Blakewater Road
Blackburn
Lancashire
BB1 5BG
LAVENDER MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2022
31 December 2022
- 2 -
2022
2021
Notes
£
£
£
£
Fixed assets
Tangible assets
5
341,079
161,751
Current assets
Stocks
1,455,775
1,363,590
Debtors
6
904,869
515,559
Cash at bank and in hand
291,932
222,749
2,652,576
2,101,898
Creditors: amounts falling due within one year
7
(1,169,686)
(611,289)
Net current assets
1,482,890
1,490,609
Total assets less current liabilities
1,823,969
1,652,360
Creditors: amounts falling due after more than one year
8
(1,472,802)
(1,560,897)
Provisions for liabilities
(48,782)
(16,778)
Net assets
302,385
74,685
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
302,285
74,585
Total equity
302,385
74,685

The director of the company has elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 December 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

LAVENDER MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 DECEMBER 2022
31 December 2022
- 3 -
The financial statements were approved and signed by the director and authorised for issue on 15 August 2023
Mr R S Saab
Director
Company Registration No. 06828106
LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022
- 4 -
1
Accounting policies
Company information

Lavender Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is 11 Amor Way, Letchworth Garden City, Hertfordshire, United \Kingdom, SG6 1UG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
25% on cost
1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 5 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% on cost
Fixtures and fittings
25% on cost
Computers
25% on cost
Motor vehicles
20% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 6 -
1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 7 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 8 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2022
2021
Number
Number
Total
22
17
4
Intangible fixed assets
Software
£
Cost
At 1 January 2022 and 31 December 2022
10,288
Amortisation and impairment
At 1 January 2022 and 31 December 2022
10,288
Carrying amount
At 31 December 2022
-
0
At 31 December 2021
-
0
LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 9 -
5
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2022
772,443
22,876
66,576
-
0
861,895
Additions
240,257
13,603
11,449
66,730
332,039
At 31 December 2022
1,012,700
36,479
78,025
66,730
1,193,934
Depreciation and impairment
At 1 January 2022
623,390
18,200
58,554
-
0
700,144
Depreciation charged in the year
139,592
2,491
5,005
5,623
152,711
At 31 December 2022
762,982
20,691
63,559
5,623
852,855
Carrying amount
At 31 December 2022
249,718
15,788
14,466
61,107
341,079
At 31 December 2021
149,053
4,676
8,022
-
0
161,751
6
Debtors
2022
2021
Amounts falling due within one year:
£
£
Trade debtors
795,801
469,692
Other debtors
109,068
45,867
904,869
515,559
7
Creditors: amounts falling due within one year
2022
2021
£
£
Bank loans
93,336
93,336
Trade creditors
699,998
258,237
Corporation tax
5,580
-
0
Other taxation and social security
233,148
148,220
Other creditors
137,624
111,496
1,169,686
611,289
LAVENDER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 10 -
8
Creditors: amounts falling due after more than one year
2022
2021
£
£
Bank loans and overdrafts
225,553
318,886
Other creditors
1,247,249
1,242,011
1,472,802
1,560,897
9
Loans and overdrafts
2022
2021
£
£
Bank loans
318,889
412,222
Other loans
1,202,011
1,242,011
1,520,900
1,654,233
Payable within one year
93,336
93,336
Payable after one year
1,427,564
1,560,897

The bank loans are secured by fixed and floating charges over the assets.

2022-12-312022-01-01false15 August 2023CCH SoftwareCCH Accounts Production 2023.100No description of principal activityMr R S SaabMr S S Saab068281062022-01-012022-12-3106828106bus:Director12022-01-012022-12-3106828106bus:CompanySecretary12022-01-012022-12-3106828106bus:RegisteredOffice2022-01-012022-12-31068281062022-12-31068281062021-12-3106828106core:PlantMachinery2022-12-3106828106core:FurnitureFittings2022-12-3106828106core:ComputerEquipment2022-12-3106828106core:MotorVehicles2022-12-3106828106core:PlantMachinery2021-12-3106828106core:FurnitureFittings2021-12-3106828106core:ComputerEquipment2021-12-3106828106core:MotorVehicles2021-12-3106828106core:CurrentFinancialInstrumentscore:WithinOneYear2022-12-3106828106core:CurrentFinancialInstrumentscore:WithinOneYear2021-12-3106828106core:Non-currentFinancialInstrumentscore:AfterOneYear2022-12-3106828106core:Non-currentFinancialInstrumentscore:AfterOneYear2021-12-3106828106core:CurrentFinancialInstruments2022-12-3106828106core:CurrentFinancialInstruments2021-12-3106828106core:Non-currentFinancialInstruments2022-12-3106828106core:Non-currentFinancialInstruments2021-12-3106828106core:ShareCapital2022-12-3106828106core:ShareCapital2021-12-3106828106core:RetainedEarningsAccumulatedLosses2022-12-3106828106core:RetainedEarningsAccumulatedLosses2021-12-3106828106core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3106828106core:ComputerSoftware2022-01-012022-12-3106828106core:PlantMachinery2022-01-012022-12-3106828106core:FurnitureFittings2022-01-012022-12-3106828106core:ComputerEquipment2022-01-012022-12-3106828106core:MotorVehicles2022-01-012022-12-31068281062021-04-012021-12-3106828106core:ComputerSoftware2021-12-3106828106core:ComputerSoftware2022-12-3106828106core:ComputerSoftware2021-12-3106828106core:PlantMachinery2021-12-3106828106core:FurnitureFittings2021-12-3106828106core:ComputerEquipment2021-12-3106828106core:MotorVehicles2021-12-31068281062021-12-3106828106core:WithinOneYear2022-12-3106828106core:WithinOneYear2021-12-3106828106bus:PrivateLimitedCompanyLtd2022-01-012022-12-3106828106bus:SmallCompaniesRegimeForAccounts2022-01-012022-12-3106828106bus:FRS1022022-01-012022-12-3106828106bus:AuditExemptWithAccountantsReport2022-01-012022-12-3106828106bus:FullAccounts2022-01-012022-12-31xbrli:purexbrli:sharesiso4217:GBP